NCT05052801 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID	NCT05052801
Title	Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression (FORTITUDE-101)
Acronym	FORTITUDE-101
Recruitment	Active, not recruiting
Gender	both
Phase	Phase III
Variant Requirements	Yes
Sponsors	Amgen
Indications	stomach cancer gastric adenocarcinoma gastroesophageal junction adenocarcinoma
Therapies	Bemarituzumab + Fluorouracil + Leucovorin + Oxaliplatin Fluorouracil + Leucovorin + Oxaliplatin
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SWE \| ROU \| POL \| NOR \| LVA \| LTU \| ITA \| ISR \| IRL \| HUN \| GRC \| FRA \| EST \| ESP \| DNK \| CZE \| CAN \| BRA \| BGR \| BEL \| AUS \| ARG

Additional content available in CKB BOOST